Stephen Rose

NIF Board Member

 

Professor Rose is Head of Clinical Development at AdvanCell Isotopes, an Australian-based radiopharmaceutical company developing next generation therapies for the treatment of cancer.

He has over 25 years’ experience in clinical R&D domain within the academic sector along with the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australia’s national science agency. Prof Rose works closely with clinicians developing the next generation of molecular imaging, therapeutic and diagnostic platforms targeting the oncology sector.